[1]周腾腾,郑 莹,梁恵卿,等.蛋白质组学在慢性乙型肝炎常见中医证型中的研究[J].医学信息,2019,(20):30-32,36.[doi:10.3969/j.issn.1006-1959.2019.20.009]
 ZHOU Teng-teng,ZHENG Ying,LIANG Hui-qing,et al.Study on Proteomics in Common TCM Syndromes of Chronic Hepatitis B[J].Medical Information,2019,(20):30-32,36.[doi:10.3969/j.issn.1006-1959.2019.20.009]
点击复制

蛋白质组学在慢性乙型肝炎常见中医证型中的研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年20期
页码:
30-32,36
栏目:
综述
出版日期:
2019-10-15

文章信息/Info

Title:
Study on Proteomics in Common TCM Syndromes of Chronic Hepatitis B
文章编号:
1006-1959(2019)20-0030-04
作者:
周腾腾1郑 莹2梁恵卿2唐金模2
(1.福建中医药大学,福建 福州 351012;2.福建中医药大学附属厦门中医院,福建 厦门 361009)
Author(s):
ZHOU Teng-teng1ZHENG Ying2LIANG Hui-qing2TANG Jin-mo2
(1.Fujian University of Traditional Chinese Medicine,Fuzhou 351012,Fujian,China;2.Xiamen Traditional Chinese Medicine Hospital,Fujian University of Traditional Chinese Medicine,Xiamen 361009,Fujian,China)
关键词:
蛋白质组学慢性乙型肝炎中医证型
Keywords:
Proteomics Chronic hepatitis B TCM syndromes
分类号:
R259
DOI:
10.3969/j.issn.1006-1959.2019.20.009
文献标志码:
A
摘要:
蛋白质组学逐渐成为系统性认知疾病的一种重要方法,该方法从整体角度分析不同状态下细胞内的动态变化,与中医的整体观一致,在研究中医证候中显示出独特优势,并在认识多种疾病的中医证候上取得进展。目前蛋白质组学在研究慢性乙型肝炎发病机制及预后上取得一定成果,在慢性乙型肝炎常见中医证型差异上也取得进展。本文主要对蛋白质组学在慢性乙型肝炎常见中医证型中的研究做一综述。
Abstract:
Proteomics has gradually become an important method for systemic cognitive diseases. This method analyzes the dynamic changes in cells under different conditions from a holistic perspective. It is consistent with the overall view of TCM and shows unique advantages in the study of TCM syndromes. And made progress in understanding TCM syndromes of various diseases. At present, proteomics has made progress in studying the pathogenesis and prognosis of chronic hepatitis B, and has made progress in the differences in common TCM syndrome types of chronic hepatitis B. This article reviews the research of proteomics in common TCM syndromes of chronic hepatitis B.

参考文献/References:

[1]王贵强,王福生,成军,等.慢性乙型肝炎防治指南(2015年版)[J].中国肝脏病杂志(电子版),2015,7(3):1-18. [2]刘二丽,汪晓军.451例慢性乙型病毒性肝炎患者中医证型分布及与临床检验指标的相关性[J].中华中医药杂志,2019,34(4):1793-1795. [3]Temnov AA,Rogov KA,Sklifas AN,et al.Protective properties of the cultured stem cellproteome studied in an animal model of acetaminophen-inducedacuteliverfailure[J].Mol Biol Rep,2019, 46(3):3101-3112 [4]Yue X,Guidry JJ.Differential Protein Expression Profiles of Bronchoalveolar Lavage Fluid Following Lipopolysaccharide-Induced Direct and Indirect Lung Injury in Mice[J].Int J Mol Sci,2019,20(14):E3401. [5]Pandey A,Mann M.Proteomics to study genes and genomics[J].Nature,2000,405(6788):837-846. [6]Ding C,Li Y,Guo F,et al.A Cell-type-resolved Liver Proteome[J].Mol Cell Proteomics,2016,15(10):3190-3202. [7]Dapic I,Baljeu-Neuman L,Uwugiaren N,et al.Proteome analysis of tissues by mass spectrometry[J].Mass Spectrom Rev,2019,38(4-5):403-441. [8]朱明丹,杜武勋,姜民,等.中医证候与基因、蛋白质、代谢组学研究思路探讨[J].中国中医基础医学杂志,2010,16(1):69-71. [9]周红光,陈海彬,周学平,等.蛋白质组学是中医病机研究的重要技术平台[J].中国中西医结合杂志,2012,32(7):990-993. [10]陈少宗,齐向华,祝世讷.系统中医学视域下的中医精准医疗[J].山东中医杂志,2019(6):503-507,518. [11]胡小勤,曾学文,岑卫健,等.高血压病气虚血瘀证和肝阳上亢证比较蛋白质组学初步研究[J].中华中医药杂志,2013,28(2):532-534. [12]熊新贵,梁清华,候俊良,等.高血压脑出血肝阳化风证与肝阳上亢证患者血清蛋白质组学研究[J].实用预防医学,2007,14(6):1649-1650. [13]王刚,姜民,朱明丹,等.冠心病心血瘀阻证和心肾阴虚证的蛋白组学研究[J].辽宁中医杂志,2011,38(3):405-407. [14]卢德赵.肾阳虚大鼠肝线粒体蛋白组变化及温补肾阳药作用机制的研究[D].北京中医药大学,2008. [15]Liu F ,Seto W ,Wong D ,et al.Plasma fibronectin levels identified via quantitative proteomics profiling predicts hepatitis B surface antigen seroclearance in chronic hepatitis B[J].The Journal of Infectious Diseases,2019. [16]Dai YN,Tu YX,Meng D,et al.Serum Proteomic Changes as Candidate Biomarkers of Intermediate Liver Fibrosis in Chronic Hepatitis B Infection[J].Omics,2019,23(3):167-179. [17]Makjaroen J,Somparn P,Hodge K,et al.Comprehensive Proteomics Identification of IFN-λ3-regulated Antiviral Proteins in HBV-transfected Cells[J].Mol Cell Proteomics,2018,17(11):2197-2215. [18]She S,Yang M,Hu H,et al.Proteomics Based Identification of Autotaxin As An Anti-Hepatitis B Virus Factor and a Promoter of Hepatoma Cell Invasion and Migration[J].Cell Physiol Biochem,2018,45(2):744-760. [19]中华中医药学会肝胆病专业委员会,中国民族医药学会肝病专业委员会.慢性乙型肝炎中医诊疗指南(2018年版)[J].临床肝胆病杂志,2018,34(12):2520-2525. [20]周明德.基于药物干预的慢性乙型肝炎肝郁脾虚证特征性蛋白的验证研究[D].成都中医药大学,2017. [21]杨健坤.慢性乙型肝炎肝郁脾虚证与脾胃湿热证血清蛋白组学验证研究[D].成都中医药大学,2016. [22]杨利超.慢性乙型病毒性肝炎肝郁脾虚与脾胃湿热证蛋白组学研究[D].成都中医药大学,2015. [23]Jiankun Y,Lichao Y,Baixue L,et al.iTRAQ-Based Proteomics Identification of Serum Biomarkers of Two Chronic Hepatitis B Subtypes Diagnosed by Traditional Chinese Medicine[J].Bio Med Research International,2016(2016):1-29. [24]陈文莉,罗鸣,陈小苹,等.慢性乙型肝炎同病异证发病的分子机制:蛋白质组学分析[J].南方医科大学学报,2016,36(3):410-413. [25]冯培民,钟森.基于同位素标记的相对和绝对定量(iTRAQ-4plex)结合液相色谱和质谱串联(LC-MS/MS)的蛋白质组学定量分析技术的慢性乙肝证候差异蛋白组学研究[A]//第二十九届全国中西医结合消化系统疾病学术会议论文集[C].2017. [26]郭芳宏.慢性乙肝中医湿热中阻、肝郁脾虚、瘀血阻络证蛋白质组学初步研究[D].泸州医学院,2010.

相似文献/References:

[1]林晓岚,郑丽花,陈苑莉,等.微信随访对慢性乙型肝炎患者抗病毒治疗效果和 生活质量的影响研究[J].医学信息,2018,(10):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
 LIN Xiao-lan,ZHENG Li-hua,CHEN Yuan-li,et al.Effect of WeChat Follow-up on Antiviral Treatment and Quality of Life in Patients with Chronic Hepatitis B[J].Medical Information,2018,(20):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
[2]林晓岚,陈苑莉.慢性乙型肝炎患者治疗依从性及其对生活质量的影响[J].医学信息,2018,(13):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
 LIN Xiao-lan,CHEN Yuan-li.Treatment Compliance of Patients with Chronic Hepatitis B and its Influence on Quality of Life[J].Medical Information,2018,(20):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
[3]吴 刚,吴锦瑜.HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的 检测及临床意义[J].医学信息,2018,(19):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
 WU Gang,WU Jin-yu.Detection and Clinical Significance of Serum 25-hydroxyvitamin D3 in Patients with HBeAg-negative Chronic Hepatitis B[J].Medical Information,2018,(20):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
[4]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
 YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Medical Information,2018,(20):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[5]陈仙梅,郭 硕,袁 丽,等.高发区早期贲门癌及癌前病变蛋白质组学中的应用研究[J].医学信息,2018,(23):72.[doi:10.3969/j.issn.1006-1959.2018.23.020]
 CHEN Xian-mei,GUO Shuo,YUAN Li,et al.Application of Proteomics in Early Gastric Cardiac Cancer and Precancerous Lesions in the High Incidence Area[J].Medical Information,2018,(20):72.[doi:10.3969/j.issn.1006-1959.2018.23.020]
[6]汪晓凤,邵和军.慢性乙型肝炎抗病毒治疗进展[J].医学信息,2019,(04):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
 WANG Xiao-feng,SHAO He-jun.Progress in Antiviral Therapy for Chronic Hepatitis B[J].Medical Information,2019,(20):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
[7]傅 蕊,李士欣,周国强,等.床旁超声预测慢性乙型肝炎患者胃镜检查围麻醉期误吸风险的临床价值[J].医学信息,2019,(08):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
 FU Rui,LI Shi-xin,ZHOU Guo-qiang,et al.Clinical Value of Bedside Ultrasound in Predicting the Risk of Aspiration during Perioperative Anesthesia in Patients with Chronic Hepatitis B[J].Medical Information,2019,(20):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
[8]张媛媛,徐 曼.慢性乙型肝炎患者e抗原消失的临床特点[J].医学信息,2019,(10):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
 ZHANG Yuan-yuan,XU Man.Clinical Features of e Antigen Disappearance in Patients with Chronic Hepatitis B[J].Medical Information,2019,(20):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
[9]罗 丹,梁惠卿,吴耀南.吴耀南教授基于“伏邪”理论治疗慢性乙肝的验案举隅[J].医学信息,2019,(19):158.[doi:10.3969/j.issn.1006-1959.2019.19.052]
[10]陈 欢,李秀惠.急、慢性乙型肝炎及乙肝肝硬化患者 肝功能及血脂水平分析[J].医学信息,2019,(12):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
 CHEN Huan,LI Xiu-hui.Analysis of Liver Function and Blood Lipid Levels in Patients with Acute, Chronic Hepatitis B and Hepatitis B Cirrhosis[J].Medical Information,2019,(20):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]

更新日期/Last Update: 2019-10-15